NCT05942287 (SLEnDR) is a NA clinical trial of Diet intervention in Heart Failure, sponsored by University of Oxford.

Who is sponsoring NCT05942287?

NCT05942287 is sponsored by University of Oxford.

What drugs are being tested in NCT05942287?

Interventions in NCT05942287: Diet intervention.

What condition does NCT05942287 study?

NCT05942287 studies Heart Failure, Heart Failure With Reduced Ejection Fraction, Obesity, Overweight.

Is NCT05942287 still recruiting?

NCT05942287 is currently recruiting now. Last updated 25 February 2025.

Last reviewed 2025-02-25 · How we verify

NCT05942287: SLEnDR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.

Recruiting now NA Last updated 25 February 2025

What this trial tests

NA trial testing Diet intervention in Heart Failure in 110 participants. Currently enrolling.

Timeline

24 May 2023

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	110
Start date	24 May 2023
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	2 locations across Jersey, United Kingdom

Drugs / interventions tested

Diet intervention

Conditions studied

Heart Failure — all drugs for Heart Failure →
Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →
Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →

Sponsor

University of Oxford

Who can join

Adults 18 to 85, any sex, with Heart Failure or Heart Failure With Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study looks at the effects of weight loss in people who have heart failure with reduced ejection fraction (HFpEF) and are overweight or obese. The main questions it aims to answer are whether weight loss in this group of people improves: * The heart's shape and how well it pumps blood * The person's quality of life and how much they can exercise Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits. Each study visit may involve measurements including: Symptom and quality of life questionnaires Body measurements such as height and weight Blood tests Ultrasound scans of the heart (echocardiogram) Magnetic Resonance Imaging (MRI) scans of the heart 6 minute walk test Participants are randomly allocated (in other words, by lottery) to either 'diet' or 'control' groups. The control group will continue standard care. The diet group will be enrolled in a weight loss program supervised by the study team. Participants in the diet group will replace their usual meals with meal replacement products specifically designed to deliver a low calorie diet for weight loss. The products will consist of formula soups, shakes and porridges. This diet would last 8 weeks, followed by a guided period of food reintroduction and maintenance.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Obesity and heart failure: exploring the cardiometabolic axis.
Rayner JJ, Abdesselam I, Pan J, Lewis AJM, et al · · 2025 · cited 4× · PMID 40458047 · DOI 10.1093/cvr/cvaf090
Targeting Obesity for Heart Failure.
Morris E, Rider O. · · 2025 · PMID 41523265 · DOI 10.15420/ecr.2025.37
Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.
Hullon D, Janiec K, Florova V, Trach A, et al · · 2025 · PMID 40978810 · DOI 10.1097/xce.0000000000000344

Verify or expand the search:

Other trials of Diet intervention

Trials testing the same drug.

NCT05960396 — Exploring the Mechanism of Dietary Pattern Improving MAFLD · NA · unknown
NCT05887674 — Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease · NA · recruiting
NCT05025943 — Omega-3 Fatty Acid Dietary Intervention (O3DI) · NA · completed
NCT04930276 — Diet-glucose-gut Microbiome Net in Women With GDM · NA · unknown
NCT04744974 — Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm · Phase 2 · completed

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05942287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 25 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05942287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing